Induction of choleresis by immunosuppressant FK506 through stimulation of insulin-like growth factor-I production in the liver of rats

European Journal of Pharmacology

Volumn 419, Issue 1, 2001, Pages 99-105

  Kawamura, Ikuo ^a   Takeshita, Shigeru ^a   Fushimi, Mariko ^a   Mabuchi, Miyuki ^a   Seki, Jiro ^a   Goto, Toshio ^a  

^a ASTELLAS PHARMA INC   (Japan)

Author keywords

Bile flow; Choleresis; Cholestasis; Cyclosporin A; FK506 (Tacrolimus); IGF I (Insulin like growth factor I)

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BILE ACID; BILIRUBIN; CYCLOSPORIN A; IMMUNOSUPPRESSIVE AGENT; PLACEBO; SOMATOMEDIN C; TACROLIMUS;

ABDOMINAL AORTA; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BILE DUCT; BILE FLOW; BLOOD SAMPLING; CANNULATION; CONTROLLED STUDY; DRUG EFFECT; HYPOPHYSECTOMY; IMMUNOSUPPRESSIVE TREATMENT; LIVER; MALE; NONHUMAN; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RAT;

ANIMALS; BILE; CYCLOSPORINE; HYPOPHYSECTOMY; IMMUNOSUPPRESSIVE AGENTS; INSULIN-LIKE GROWTH FACTOR I; LIVER; MALE; RATS; RATS, SPRAGUE-DAWLEY; TACROLIMUS;

EID: 0035805284     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(01)00961-X     Document Type: Article

References (40)

1. Chan F.K.L., Shaffer E.A. Cholestatic effects of cyclosporine in the rat. Transplantation. 63:1997;1574-1578.
2. Clipstone N.A., Crabtree G.R. Identification of calcineurin as a key signalling enzyme in T-lymphocyte activation. Nature. 357:1992;695-697.
3. Dore S., Kar S., Quirion R. Rediscovering an old friend, IGF-I: potential use in the treatment of neurodegenerative diseases. Trends Neurosci. 20:1997;326-331.
4. Ericzon B.G., Eusufzai S., Kubota K., Einarsson K., Angelin B. Characteristics of biliary lipid metabolism after liver transplantation. Hepatology. 12:1990;1221-1228.
5. Ericzon B.G., Eusufzai S., Söderdahl G., Duraj F., Einarsson K., Angelin B. Secretion and composition of bile after human liver transplantation: studies on the effects of cyclosporine and tacrolimus. Transplantation. 63:1997;74-80.
6. Randomised trial comparing tacrolimus (FK506) and cyclosporine in prevention of liver allograft rejection. Lancet. 344:1994;423-428.
7. Friedman J., Weissman I. Two cytoplasmic candidates for immunophilin action are revealed by affinity for a new cyclophilin: one in the presence and one in the absence of CsA. Cell. 66:1991;799-806.
8. Goto T., Kino T., Hatanaka H., Okuhara M., Kohsaka M., Aoki H., Imanaka H. FK506: historical perspectives. Transplant. Proc. 23:1991;2713-2717.
9. Griffith B.P., Bando K., Hardesty R.L., Armitage J.M., Keenan R.J., Pham S.M., Paradis I.L., Yousem S.A., Komatsu K., Konishi H., Fung J.J., Starzl T.E. A prospective randomized trial of FK506 versus cyclosporine after human pulmonary transplantation. Transplantation. 57:1994;848-851.
10. Herrera J., Codoceo R., Mora N.P., Pereira F., Jara P., Pardo F., Cienfuegos J.A., Castillo-Olivares J.L. Bile acid profile as an early indicator of allograft function during orthotopic liver transplantation. Transplant. Proc. 21:1989;2313-2314.
11. Isai H., Painter D.M., Sheil A.G.R. FK506 and orthotopic liver transplantation in the rat. Transplant. Proc. 22:1990;2125-2126.
12. Jiang H., Takahara S., Takano Y., Li D., Kyo M., Valdivia L.A., Kokado Y., Ishibashi M., Sonoda T. Effect of FK506 on heart allograft survival in highly sensitized recipient rats in comparison with cyclosporine. Transplant. Proc. 23:1991;540-541.
13. Kawamura I., Takeshita S., Fushimi M., Mabuchi M., Seki J., Tomoi M., Goto T. Stimulation of choleresis by insulin-like growth factor-I in rats. Endocr. J. 47:2000;249-255.
14. Kino T., Hatanaka H., Hashimoto M., Nishiyama M., Goto T., Okuhara M., Kohsaka M., Aoki H., Imanaka H. FK-506, a novel immunosuppressant isolated from a Streptomyces: I. Fermentation, isolation, and physico-chemical and biological characteristics. J. Antibiot. (Tokyo). 40:1987;1249-1255.
15. Kino T., Hatanaka H., Miyata S., Inamura N., Nishiyama M., Yajima T., Goto T., Okuhara M., Kohsaka M., Aoki H., Ochiai T. FK-506, a novel immunosuppressant isolated from a Streptomyces: II. Immunosuppressive effect of FK-506 in vitro. J. Antibiot. (Tokyo). 40:1987;1256-1265.
16. Kino T., Inamura N., Sakai F., Nakahara K., Goto T., Okuhara M., Kohsaka M., Aoki H., Ochiai T. Effect of FK-506 on human mixed lymphocyte reaction in vitro. Transplant. Proc. 19(Suppl. 6):1987;36-39.
17. Klintmalm G.B., Iwatsuki S., Starzl T.E. Cyclosporin A hepatotoxicity in 66 renal allograft recipients. Transplantation. 32:1981;488-489.
18. Lang T., Sendl A.F., Esquivel C.O., Berquist W.E., Cox K.L. Cholic acid synthesis is reduced in pediatric liver recipients during graft dysfunction due to ischemic injury and allograft rejection. Transplantation. 64:1997;1585-1590.
19. Laupacis A., Keown P.A., Ulan R.A., Sinclair N.R., Stiller C.R. Hyperbilirubinaemia and cyclosporine A levels. Lancet II. 1981;1426-1427.
20. Liu J., Farmer J.D. Jr., Lane W.S., Friedman J., Weissman I., Schreiber S.L. Calcineurin is a common target of cyclophilin-cyclosporine A and FKBP-FK506 complexes. Cell. 66:1991;807-815.
21. McCashland T.M., Donovan J.P., Amelsberg A., Rossi S.S., Hofmann A.F., Shaw B.W. Jr., Quigley E.M.M. Bile acid metabolism and biliary secretion in patients receiving orthotopic liver transplants: differing effects of cyclosporine and FK506. Hepatology. 19:1994;1381-1389.
22. McDiarmid S.V., Busuttil R.W., Ascher N.L., Burdick J., D'Alessandro A.M., Esquivel C., Kalayoglu M., Klein A.S., Marsh J.W., Miller C.M., Schwartz M.E., Shaw B.W., So S.K. FK506 (tacrolimus) compared with cyclosporine for primary immunosuppression after pediatric liver transplantation: Results from the US multicenter trial. Transplantation. 59:1995;530-536.
23. Mizuta K., Kobayashi E., Uchida H., Fujimura A., Kawarasaki H., Hashizume K. Influence of tacrolimus on bile acid and lipid composition in continuously drained bile using a rat model: Comparative study with cyclosporine. Transpl., Int. 12:1999;316-322.
24. Murao K., Sato M., Niimi M., Wada Y., Matsubara S., Takahara J. Immunosuppressant agent FK506 stimulates growth hormone (GH) secretion and gene expression of hypothalamic GH-releasing hormone in the rat. Endocrinology. 137:1996;1118-1122.
25. Murphy L.J., Bell G.I., Friesen H.G. Tissue distribution of insulin-like growth factor I and II messenger ribonucleic acid in the adult rat. Endocrinology. 120:1987;1279-1282.
26. Ochiai T., Nagata M., Nakajima K., Suzuki T., Sakamoto K., Enomoto K., Gunji Y., Uematsu T., Goto T., Hori S., Kenmochi T., Nakagouri T., Asano T., Isono K., Hamaguchi K., Tsuchida H., Nakahara K., Inamura N., Goto T. Studies of the effects of FK506 on renal allografting in the beagle dog. Transplantation. 44:1987;729-733.
27. Ochiai T., Nakajima K., Nagata M., Suzuki T., Asano T., Uematsu T., Goto T., Hori S., Kenmochi T., Nakagoori T., Isono K. Effect of a new immunosuppressive agent, FK506, on heterotopic cardiac allotransplantation in the rat. Transplant. Proc. 19:1987;1284-1286.
28. O'Keefe S.J., Tamura J., Kincaid R.L., Tocci M.J., O'Neill E.A. FK-506- and CsA-sensitive activation of the interleukin-2 promoter by calcineurin. Nature. 357:1992;692-694.
29. Pirsch J.D., Miller J., Deierhoi M.H., Vincenti F., Filo R.S. A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. Transplantation. 63:1997;977-983.
30. Roman I.D., Monte M.J., Gonzalez-Buitrago J.M., Esteller A., Jimenez R. Inhibition of hepatocytary vesicular transport by cyclosporine A in the rat: relationship with cholestasis and hyperbilirubinemia. Hepatology. 12:1990;83-91.
31. Rotwein P. Two insulin-like growth factor I messenger RNAs are expressed in human liver. Proc. Natl. Acad. Sci. U. S. A. 83:1986;77-81.
32. Sanchez-Campos S., Lopez-Acebo R., Gonzalez P., Culebras J.M., Tunon M.J., Gonzalez-Gallego J. Cholestasis and alterations of glutathione metabolism induced by tacrolimus (FK506) in the rat. Tranplantation. 66:1998;84-88.
33. Sigal N.H., Lin C.S., Siekierka J.J. Inhibition of human T-cell activation by FK506, rapamycin, and cyclosporine A. Transplant. Proc. 23(Suppl. 2):1991;1-5.
34. Stone B.G., Udani M., Sanghvi A., Warty V., Plocki K., Bedetti C.D., Van Thiel D.H. Cyclosporine A-induced cholestasis. The mechanism in a rat model. Gastroenterology. 93:1987;344-351.
35. Tamura K., Fujimura T., Tsutsumi T., Nakamura K., Ogawa T., Atumaru C., Hirano Y., Ohara K., Ohtsuka K., Shimomura K., Kobayashi M. Transcriptional inhibition of insulin by FK506 and possible involvement of FK506 binding protein-12 in pancreatic β-cell. Transplantation. 59:1995;1606-1613.
36. A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression in liver transplantation. N. Eng. J. Med. 331:1994;1110-1115.
37. Theilmann L., Otto G., Arnold J., Gmelin K., Stiehl A. Biliary secretion of bile acids, lipids, and bilirubin by the transplanted liver: A quantitative study in patients on cyclosporine. Transplantation. 52:1991;1020-1023.
38. Thissen J.P., Triest S., Moats-staats B.M., Underwood L.E., Mauerhoff T., Maiter D., Ketelslegers J.M. Evidence that pretranslational and translational defects decrease serum insulin-like growth factor-I concentrations during dietary protein restriction. Endocrinology. 129:1991;429-435.
39. Todo S., Fung J.J., Starzl T.E., Tzakis A., Demertris A.J., Kormos R., Jain A., Alessiani M., Takaya S., Shapiro R. Liver, kidney, and thoracic organ transplantation under FK506. Ann. Surg. 212:1990;295-307.
40. Wiesner R.H. A long-term comparison of tacrolimus (FK506) versus cyclosporine in liver transplantation. A report of the United States FK506 study group. Transplantation. 66:1998;493-499.